Compare ATKR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATKR | MLYS |
|---|---|---|
| Founded | 1959 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2016 | 2023 |
| Metric | ATKR | MLYS |
|---|---|---|
| Price | $59.44 | $26.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $75.67 | $47.33 |
| AVG Volume (30 Days) | 224.4K | ★ 975.3K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $2,850,378,000.00 | N/A |
| Revenue This Year | $6.86 | N/A |
| Revenue Next Year | $3.94 | N/A |
| P/E Ratio | $139.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $49.92 | $10.44 |
| 52 Week High | $80.06 | $47.65 |
| Indicator | ATKR | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 30.48 | 35.82 |
| Support Level | $58.75 | $12.98 |
| Resistance Level | $60.48 | $30.05 |
| Average True Range (ATR) | 1.74 | 1.47 |
| MACD | -0.55 | -0.03 |
| Stochastic Oscillator | 7.86 | 25.68 |
Atkore Inc is a manufacturer of Electrical products for the non-residential construction and renovation markets, as well as residential markets, and Safety & Infrastructure products for the construction and industrial markets. The Electrical segment manufactures products used in the construction of electrical power systems including conduit, cable, and installation accessories. This segment serves contractors in partnership with the electrical wholesale channel. The Safety & Infrastructure segment designs and manufactures solutions including metal framing, mechanical pipe, perimeter security, and cable management. These solutions are marketed to contractors, original equipment manufacturers (OEMs), and end-users. The majority of revenue is generated from the Electrical segment.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.